Human Pathology
Volume 41, Issue 6 , Pages 794-804, June 2010

Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma☆

  • Mari Bunkholt Elstrand, MD

      Affiliations

    • Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Hiep Phuc Dong, MSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Elin Ødegaard, MD, PhD

      Affiliations

    • Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Arild Holth, BSc

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • ,
  • Sivan Elloul, MSc

      Affiliations

    • Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
    • ,
  • Reuven Reich, PhD

      Affiliations

    • Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
    • ,
  • Claes G. Tropé, MD, PhD

      Affiliations

    • Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • Faculty Division Radiumhospitalet, the Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N-0310 Oslo, Norway
    • Faculty Division Radiumhospitalet, the Medical Faculty, University of Oslo, N-0316 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Department of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello, N-0310 Oslo, Norway.

Received 29 May 2009; received in revised form 28 August 2009; accepted 22 September 2009. published online 15 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Financial acknowledgement: This work was supported by grants from the Norwegian Cancer Society (Olso, Norway), the Health Region of South-Eastern Norway (Hamar, Norway), and the Inger and Jon Fredriksen Foundation for Ovarian Cancer Research (Olso, Norway).

PII: S0046-8177(09)00426-2

doi:10.1016/j.humpath.2009.09.017

Human Pathology
Volume 41, Issue 6 , Pages 794-804, June 2010

Article Tools

* Image Usage & Resolution